PACran Cranberry Powder Health Claim Approved by Korean FDA

The extensive approval process for PACran took nearly two years to complete and was obtained after DBS and its Korean partner, Monature, submitted a complete clinical dossier including the required safety data.

14 Dec 2009 --- Decas Botanical Synergies, LLC. (DBS), manufacturer of PACran, the first clinically supported and proanthocyanidin (PAC) standardized cranberry powder, has obtained Korean Food and Drug Administration (KFDA) approval for a health claim supporting urinary health. This approval is the first health food product by KFDA for urinary health and only PACran can make this claim in Korea.

In 2004, the KFDA enforced the approval system of functional ingredients for the Health Function Food market according to the law of Health Functional Food. The extensive approval process for PACran took nearly two years to complete and was obtained after DBS and its Korean partner, Monature, submitted a complete clinical dossier including the required safety data.

“We are excited about the Korean FDA approval and the new opportunities for PACran it will offer, “ said Daniel Souza, DBS director of sales and marketing. “We continue to invest in research to scientifically validate our products which allows us to clearly distinguish ourselves. DBS continues to lead the global market with the most cost effective and efficacious cranberry products available.”